Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Therapeutical approach to plasma homocysteine and cardiovascular risk reduction

Authors Marcello Ciaccio, Giulia Bivona, Chiara Bellia

Published 8 February 2008 Volume 2008:4(1) Pages 219—224

DOI https://doi.org/10.2147/TCRM.S1807

Marcello Ciaccio, Giulia Bivona, Chiara Bellia

Department of Medical Biotechnologies and Forensic Medicine, Faculty of Medicine, University of Palermo, Italy

Abstract: Homocysteine is a sulfur-containing aminoacid produced during metabolism of methionine. Since 1969 the relationship between altered homocysteine metabolism and both coronary and peripheral atherotrombosis is known; in recent years experimental evidences have shown that elevated plasma levels of homocysteine are associated with an increased risk of atherosclerosis and cardiovascular ischemic events. Several mechanisms by which elevated homocysteine impairs vascular function have been proposed, including impairment of endothelial function, production of reactive oxygen species (ROS) and consequent oxidation of low-density lipids. Endothelial function is altered in subjects with hyperhomocysteinemia, and endothelial dysfunction is correlated with plasma levels of homocysteine. Folic acid and B vitamins, required for remethylation of homocysteine to methionine, are the most important dietary determinants of homocysteine and daily supplementation typically lowers plasma homocysteine levels; it is still unclear whether the decreased plasma levels of homocysteine through diet or drugs may be paralleled by a reduction in cardiovascular risk.

Keywords: homocysteine, MTHFR, cardiovascular disease, folate, B vitamin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

Caruso A, Bellia C, Pivetti A, Agnello L, Bazza F, Scazzone C, Bivona G, Lo Sasso B, Ciaccio M

Pharmacogenomics and Personalized Medicine 2014, 7:117-120

Published Date: 2 April 2014

Readers of this article also read:

Today's diverse nano-theranostic applications and tomorrow's promises

Webster TJ, Lee S, An SSA

International Journal of Nanomedicine 2015, 10:1-2

Published Date: 25 August 2015

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation

Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, Yamagishi T, Kubo T, Tanimoto M, Kiura K, Takigawa N

Drug Design, Development and Therapy 2014, 8:2401-2408

Published Date: 3 December 2014

Review: management of Parkinson's disease

Pedrosa DJ, Timmermann L

Neuropsychiatric Disease and Treatment 2013, 9:321-340

Published Date: 3 March 2013

A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery

Li P, Liu DH, Miao L, Liu CX, Sun XL, Liu YJ, Zhang N

International Journal of Nanomedicine 2012, 7:925-939

Published Date: 21 February 2012

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Portal vein thrombosis in a patient with HCV cirrhosis and combined hemophilia A and thrombophilia V Leiden

Nikos Eleftheriadis, Pantelis Makris

Therapeutics and Clinical Risk Management 2010, 6:539-541

Published Date: 26 October 2010